| __timestamp | Rhythm Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 1213000 | 612613000000 |
| Thursday, January 1, 2015 | 3425000 | 650773000000 |
| Friday, January 1, 2016 | 6311000 | 619061000000 |
| Sunday, January 1, 2017 | 9518000 | 628106000000 |
| Monday, January 1, 2018 | 28080000 | 717599000000 |
| Tuesday, January 1, 2019 | 36550000 | 964737000000 |
| Wednesday, January 1, 2020 | 46125000 | 875663000000 |
| Friday, January 1, 2021 | 68486000 | 886361000000 |
| Saturday, January 1, 2022 | 92032000 | 997309000000 |
| Sunday, January 1, 2023 | 117532000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. Takeda Pharmaceutical Company Limited, a Japanese titan, and Rhythm Pharmaceuticals, Inc., a burgeoning American firm, present a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Takeda's SG&A expenses have shown a steady increase, peaking at over 1 trillion yen in 2023, reflecting its expansive global operations. In contrast, Rhythm Pharmaceuticals, with its focus on niche markets, has seen its SG&A expenses grow from a modest 1.2 million dollars in 2014 to approximately 118 million dollars in 2023, marking a staggering 9,600% increase.
This data highlights the diverse strategies of these companies: Takeda's broad market reach versus Rhythm's targeted approach. Such insights are invaluable for investors and industry analysts alike.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Takeda Pharmaceutical Company Limited
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited vs Ascendis Pharma A/S: SG&A Expense Trends
Takeda Pharmaceutical Company Limited vs Opthea Limited: SG&A Expense Trends
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
Bio-Techne Corporation vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Rhythm Pharmaceuticals, Inc.
Alkermes plc and Rhythm Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs MannKind Corporation Trends and Insights
Cost Management Insights: SG&A Expenses for Rhythm Pharmaceuticals, Inc. and MiMedx Group, Inc.